Marilyn Mann, over at Gooznews has a very careful, cogent review of the latest FDA-reported adverse events
SEAS (my error here corrected, by Marilyn Mann's comment below -- do read it, as well) data study -- published in the April issue of the Journal of Clinical Lipidology (by authors, BTW, who report receiving speaking fees and honoraria from Schering-Plough and Merck -- huge surprise, that!), this Saturday afternoon -- do go read it all, but here is a "money" quote:
. . . .it is difficult to see how any particular case of cancer could be definitively connected to ezetimibe even if it turns out that ezetimibe causes cancer or increases the risk of cancer death. Bottom line: if you are worried about the cancer signal in SEAS, this study is unlikely to provide you any comfort. . . . .
Indeed. I am not sure a down-shifted cancer incidence rate is really a "selling point" -- for a cholesterol drug.